BGMD
vs
S&P 500
BGMD
S&P 500
Over the past 12 months, BGMD has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +12% growth.
Stocks Performance
BGMD vs S&P 500
Performance Gap
BGMD vs S&P 500
Performance By Year
BGMD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BG Medicine Inc
Glance View
BG Medicine, Inc. is a life sciences company. The company is headquartered in Foxboro, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
